284 related articles for article (PubMed ID: 31240545)
1. Bee Venom Immunotherapy: Current Status and Future Directions.
Zahirović A; Luzar J; Molek P; Kruljec N; Lunder M
Clin Rev Allergy Immunol; 2020 Jun; 58(3):326-341. PubMed ID: 31240545
[TBL] [Abstract][Full Text] [Related]
2. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom.
Müller U; Akdis CA; Fricker M; Akdis M; Blesken T; Bettens F; Blaser K
J Allergy Clin Immunol; 1998 Jun; 101(6 Pt 1):747-54. PubMed ID: 9648701
[TBL] [Abstract][Full Text] [Related]
3. Epitope peptides and immunotherapy.
Tanabe S
Curr Protein Pept Sci; 2007 Feb; 8(1):109-18. PubMed ID: 17305564
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a therapeutic treatment using gas-filled microbubble-associated phospholipase A2 in a mouse model of honeybee venom allergy.
Corthésy B; Lassus A; Terrettaz J; Tranquart F; Bioley G
Allergy; 2016 Jul; 71(7):957-66. PubMed ID: 26850222
[TBL] [Abstract][Full Text] [Related]
5. Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy.
Blank S; Etzold S; Darsow U; Schiener M; Eberlein B; Russkamp D; Wolf S; Graessel A; Biedermann T; Ollert M; Schmidt-Weber CB
Hum Vaccin Immunother; 2017 Oct; 13(10):2482-2489. PubMed ID: 28494206
[TBL] [Abstract][Full Text] [Related]
6. Intralymphatic injections as a new administration route for allergen-specific immunotherapy.
Martínez-Gómez JM; Johansen P; Erdmann I; Senti G; Crameri R; Kündig TM
Int Arch Allergy Immunol; 2009; 150(1):59-65. PubMed ID: 19339803
[TBL] [Abstract][Full Text] [Related]
7. Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy.
Frick M; Fischer J; Helbling A; Ruëff F; Wieczorek D; Ollert M; Pfützner W; Müller S; Huss-Marp J; Dorn B; Biedermann T; Lidholm J; Ruecker G; Bantleon F; Miehe M; Spillner E; Jakob T
J Allergy Clin Immunol; 2016 Dec; 138(6):1663-1671.e9. PubMed ID: 27372568
[TBL] [Abstract][Full Text] [Related]
8. Medication with antihistamines impairs allergen-specific immunotherapy in mice.
Johansen P; Senti G; Maria Martínez Gómez J; Kündig TM
Clin Exp Allergy; 2008 Mar; 38(3):512-9. PubMed ID: 18081882
[TBL] [Abstract][Full Text] [Related]
9. IgE-Api m 4 Is Useful for Identifying a Particular Phenotype of Bee Venom Allergy.
Ruiz B; Serrano P; Moreno C
J Investig Allergol Clin Immunol; 2016; 26(6):355-361. PubMed ID: 27996941
[TBL] [Abstract][Full Text] [Related]
10. Recombinant allergen-based IgE testing to distinguish bee and wasp allergy.
Mittermann I; Zidarn M; Silar M; Markovic-Housley Z; Aberer W; Korosec P; Kosnik M; Valenta R
J Allergy Clin Immunol; 2010 Jun; 125(6):1300-1307.e3. PubMed ID: 20466415
[TBL] [Abstract][Full Text] [Related]
11. Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes.
Karamloo F; Schmid-Grendelmeier P; Kussebi F; Akdis M; Salagianni M; von Beust BR; Reimers A; Zumkehr J; Soldatova L; Housley-Markovic Z; Müller U; Kündig T; Kemeny DM; Spangfort MD; Blaser K; Akdis CA
Eur J Immunol; 2005 Nov; 35(11):3268-76. PubMed ID: 16206231
[TBL] [Abstract][Full Text] [Related]
12. Allergen dose dependent cytokine production regulates specific IgE and IgG antibody production.
Blaser K
Adv Exp Med Biol; 1996; 409():295-303. PubMed ID: 9095257
[TBL] [Abstract][Full Text] [Related]
13. Immunology of Bee Venom.
Elieh Ali Komi D; Shafaghat F; Zwiener RD
Clin Rev Allergy Immunol; 2018 Jun; 54(3):386-396. PubMed ID: 28105558
[TBL] [Abstract][Full Text] [Related]
14. New insight into immunological mechanisms of venom immunotherapy.
Ewan PW
Curr Opin Allergy Clin Immunol; 2001 Aug; 1(4):367-74. PubMed ID: 11964715
[TBL] [Abstract][Full Text] [Related]
15. New developments in the diagnosis and treatment of hymenoptera venom allergy.
Müller UR
Int Arch Allergy Immunol; 2001 Apr; 124(4):447-53. PubMed ID: 11340327
[TBL] [Abstract][Full Text] [Related]
16. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy.
Kussebi F; Karamloo F; Rhyner C; Schmid-Grendelmeier P; Salagianni M; Mannhart C; Akdis M; Soldatova L; Markovic-Housley Z; Von Beust BR; Kündig T; Kemeny DM; Blaser K; Crameri R; Akdis CA
J Allergy Clin Immunol; 2005 Feb; 115(2):323-9. PubMed ID: 15696088
[TBL] [Abstract][Full Text] [Related]
17. Component resolution reveals additional major allergens in patients with honeybee venom allergy.
Köhler J; Blank S; Müller S; Bantleon F; Frick M; Huss-Marp J; Lidholm J; Spillner E; Jakob T
J Allergy Clin Immunol; 2014 May; 133(5):1383-9, 1389.e1-6. PubMed ID: 24440283
[TBL] [Abstract][Full Text] [Related]
18. The putative serine protease inhibitor Api m 6 from Apis mellifera venom: recombinant and structural evaluation.
Michel Y; McIntyre M; Ginglinger H; Ollert M; Cifuentes L; Blank S; Spillner E
J Investig Allergol Clin Immunol; 2012; 22(7):476-84. PubMed ID: 23397669
[TBL] [Abstract][Full Text] [Related]
19. Allergen-related approaches to immunotherapy.
Rolland JM; Gardner LM; O'Hehir RE
Pharmacol Ther; 2009 Mar; 121(3):273-84. PubMed ID: 19111571
[TBL] [Abstract][Full Text] [Related]
20. Safety of specific immunotherapy using an ultra-rush induction regimen in bee and wasp allergy.
Bożek A; Kołodziejczyk K
Hum Vaccin Immunother; 2018 Feb; 14(2):288-291. PubMed ID: 29106324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
